Mohammed Abdul Jawad

8 months ago · 1 min. reading time · visibility ~10 ·

chat Contact the author

thumb_up Relevant message Comment

Evaluate Vantage 2020 Review: Investors Drive Biopharma to New Heights

Evaluate Vantage 2020 Review: Investors Drive Biopharma to New HeightsOR

Evaluate Vantage FN

Review: Investors we Ye
Biopharma to New Heights

 
    

>
7

Sd

Download your copy of the latest report


Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalization, and smaller biotechs saw a record-breaking $12.8bn raised by IPO and $20bn invested by venture financers.

Fortunes in the medical device industry were more divided. Companies developing diagnostics and treatments benefitted from the continued focus on COVID-19, but other segments suffered from decreased demand, and this trend could continue into 2021.


Report Highlights — Pharma & Biotech:
  • Novovax (2,702%) and Shin Poong (1,613%) saw the greatest market cap increases by percent growth.
  • AbbVie added $58.2bn in market cap, the largest increase by value, although Eli Lilly saw a greater increase by percentage (28%).
  • GlaxoSmithKline saw the greatest share price loss among big pharma (-25%), followed by Merck & Co (-12%) and Bristol Myers Squibb (-10%).
  • The total value of  M&A transactions was $130bn, with deals announced by Astrazeneca, Gilead and Bristol Myers Squibb compensating for a slow start.
  • The FDA approved 57 novel medicines, a modest increase from 2019, with a total of $21.6 billion in fifth-year sales potential.


Report Highlights — Medtech:
  • The average size of medtech venture financing rounds reached a ten-year high at $37.4 million, a 50% increase from 2019.
  • Medtech M&A continued to decline, with 111 transactions totaling $27.3 billion closed, the lowest value since 2013.
  • The FDA approved 22 PMAs and 37 501(k) clearances, consistent with 2019 totals.



                                                                                                     * ~ * ~ *

About Evaluate Pharma: EvaluatePharma gives you a comprehensive understanding of the global pharmaceutical industry’s past, present and future performance. With over two decades of commercial data and consensus forecasts to 2026, you get a seamless 25-year view of the commercial issues driving the sector. 

From an overview of the broader market to a detailed product or company analysis, EvaluatePharma’s integrated platform is designed to take you from exploration to full understanding as quickly and accurately as possible. A series of powerful, interactive dashboards help you accelerate common tasks like market landscaping, exploring market dynamics and analyzing portfolios, so you can focus on the strategic decisions that matter.

Reduce the cost, time and risk of making strategic decisions.


thumb_up Relevant message Comment
Comments

More articles from Mohammed Abdul Jawad

View blog
2 months ago · 4 min. reading time
Mohammed Abdul Jawad

Knowing Khaled Almaeena

In no way, I had an interest for writing articles. ...

3 months ago · 1 min. reading time
Mohammed Abdul Jawad

Improving Data Quality and Efficiency and Changing Pharmaceutical Analysis

FREE WEBCAST · Available On Demand · WEBCAST TITLE ...

3 months ago · 1 min. reading time
Mohammed Abdul Jawad